Trial Profile
An Early Phase 1 Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Patients With Hepatic or Renal Dysfunction and Solid Tumors.
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 13 Mar 2024
Price :
$35
*
At a glance
- Drugs Veliparib (Primary) ; Carboplatin; Paclitaxel
- Indications Advanced breast cancer; Carcinoma; Endometrial cancer; Head and neck cancer; Lung cancer; Malignant melanoma; Oesophageal cancer; Ovarian cancer; Solid tumours; Testicular cancer; Urogenital cancer
- Focus Adverse reactions; Pharmacokinetics
- 24 May 2019 Status changed from suspended to active, no longer recruiting.
- 24 May 2019 Status changed from suspended to active, no longer recruiting.
- 17 Dec 2018 Planned primary completion date changed from 31 Jul 2017 to 31 Jul 2019.